NHI coverage possible for unregistered drugs if KFDA designates.

The MOHW disclosed a revised bill draft of "The standards for the NHI payment" that was partly revised so as even for the drugs unregistered in Korea but thought to be necessary urgently to use by the KFDA to be granted for the NHI coverage.

The revised draft provides a legislation backdrop for the orphan drugs already approved by the U. S. FDA and supplied by the Korea Orphan Drug Center to...